Reimbursement
and Support for Dermacyte Matrix
Merakris offers a comprehensive reimbursement support for providers using Dermacyte Matrix. To get your copy, complete this form.
Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1271.